|Positive WB detected in||Recombinant protein protein|
|Western Blot (WB)||WB : 1:2000-1:12000|
|Sample-dependent, check data in validation data gallery|
15365-1-AP targets IFN Gamma in WB, IHC, IF, FC, ELISA applications and shows reactivity with human samples.
|Cited Reactivity||human, rat, pig|
|Host / Isotype||Rabbit / IgG|
|Immunogen||IFN Gamma fusion protein Ag8321|
|Full Name||IFN gamma|
|Calculated molecular weight||166 aa, 19 kDa|
|GenBank accession number||BC070256|
|Gene ID (NCBI)||3458|
|Purification Method||Antigen affinity purification|
|Storage Buffer||PBS with 0.02% sodium azide and 50% glycerol pH 7.3.|
|Storage Conditions||Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.|
IFN gamma (IFNG) is a soluble cytokine that is the only member of the type II class of IFN. It is secreted by Th1 cells, cytotoxic T cells and NK cells. The cytokine is associated with antiviral, immunoregulatory and anti-tumor properties and is a potent activator of macrophages. It plays crucial roles in pathogen clearance. Aberrant IFNG expression is associated with a number of autoinflammatory and autoimmune diseases. It has been identified in many studies as a biomarker for pleural tuberculosis (TB). Mutations in this gene are associated with aplastic anemia.
J Cell Physiol
Dehydroepiandrosterone stimulates inflammation and impairs ovarian functions of polycystic ovary syndrome.
Am J Chin Med
Total Glycosides of Peony Protects Against Inflammatory Bowel Disease by Regulating IL-23/IL-17 Axis and Th17/Treg Balance.
Low-dose IFN-γ induces tumor cell stemness in the tumor microenvironment of non-small cell lung cancer.
Mol Genet Genomics
A comparison of CRISPR/Cas9 and siRNA-mediated ALDH2 gene silencing in human cell lines.
Decreased percentages of regulatory T cells are necessary to activate Th1-th17-th22 responses during acute rejection of the peripheral nerve xenotransplantation in mice.
Acta Pharm Sin B
Self-assembled FeS-based cascade bioreactor with enhanced tumor penetration and synergistic treatments to trigger robust cancer immunotherapy